Hospital

Ruxolitinib is indicated for intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease.

Senator Scott Wiener, discusses the California Senate Bill 519 he co-authored, which is the first and most expansive psychedelic decriminalization bill to go through a state legislature.

Growing demand for specialty care, shifting prescriber habits, and new reimbursement models have forced stakeholders to adjust practices to optimize patient outcomes.

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.

Seronegative patients with COVID-19 who required low-flow or no supplemental oxygen receiving Ronapreve had significant reductions in viral load within 7 days of treatment.

Trials show a consistent efficacy profile and a consistent safety profile for RBX2660 in reducing the recurrence of C. difficile infection.

A single infusion of the CAR T-cell therapy Tecartus produced a high and durable response rate in heavily pretreated patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Prescribers, pharmacists, nurses, lab technicians, and other health care professionals must work as a team to create awareness and understanding of pharmacogenomics integration.

Molnupiravir reduced the risk of hospitalization or death by approximately 50% among patients with COVID-19 who received the drug.

According to a press release from Mirum, maralixibat is the first and only FDA-approved medication to treat ALGS, a rare liver disease that affects 2000 to 2500 children in the United States.

The investigators said these results suggest patients with low sTK1 activity levels have slow-growing disease, which can be initially controlled through single-drug endocrine therapy.

Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer.

Pharmacy Times will be celebrating pharmacists throughout the month of October to recognize their contributions to the health care field.

Donna Bohannon, RPh, MS, principal scientist at US Pharmacopeia (USP), and Bhumi Khambholja, PharmD, MSHI, project manager of Wisconsin Health Literacy, discuss how to adopt USP standards for labeling to increase health equity.

Additionally, the ITT-E population showed both treatment arms showing a high proportion of participants with plasma HIV-1 RNA c/mL with dolutegravir/lamivudine demonstrating non-inferior virologic suppression to the TAF-based regimen.

Generic substitution can lower patient drug costs and improve medication adherence.

Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.

Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.

Although it may not be feasible in all situations, professional sabbatical leave could be a win-win for both pharmacists and their employers.

During atrial fibrillation, both of the heart's upper chambers beat chaotically and irregularly without coordination.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential adverse effects and drug-drug interactions with psilocybin, MDMA, and ketamine treatment.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what the role of the pharmacist is during the treatment of patients with advanced cutaneous T cell lymphoma.

The agency has given the greenlight to maralixibat after the ICONIC study combined with 5 years of supportive studies that demonstrated the reduction of pruritis.

Robert Z. Orlowski, MD, PhD, director of the Myeloma Section at the University of Texas MD Anderson Cancer Center, reviewed novel agents in the treatment of triple-class refractory myeloma during a session at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).

The recommendation for managing cytopenias among patients treated with tyrosine kinase inhibitors is to discontinue treatment at the onset of grade 3 or higher.

The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.

Although specialty pharmacies may be able to offer some of the services that a hub provider does, a hub can standardize patient and provider support across the network.

Amisulpride is a selective dopamine-2 and -3 receptor antagonist that inhibits postoperative nausea and vomiting.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses the areas that may need further investigation to progress advanced cutaneous T cell lymphoma treatments in the future.

Risk stratification for survival should not dictate treatment, but stratification for thrombosis risk should play an important role in treatment decisions.